Tobacco Use DisorderNCT05875194
Influence of tDCS on the Brain Activation Measured During the Decision Not to Smoke in High-risk Situations
A study testing active transcranial direct current stimulation (tDCS) in people with Tobacco Use Disorder, run by University Hospital Tuebingen at 1 site in Germany.
Trial summary
Substance use disorders (SUD) are characterized by increased automatized responses to drug-related cues (cue-reactivity) and deficient cognitive control. Cue-reactivity (CR) can be elicited by internal (e.g. mood) or external (e.g. situations) cues closely related to consumption. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Tobacco Use Disorder
- What is being tested?
- active transcranial direct current stimulation (tDCS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteGermany
- Study dates
- 15 Oct 2022to 15 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- informed consent
- daily cigarette consumption (already in the first half of the day)
Who cannot join
- Acute or chronic disease (also anamnestic) that may affect brain metabolism:
- pre-existing diabetes mellitus (E10-E14) according to ICD-10
- Renal insufficiency from stage 3 of the Kidney Disease Outcomes Quality Initiative onwards
- Uncontrolled hypertension (I10.x according to ICD-10)
- Moderate or severe traumatic brain injury (GCS 3-12) or 2nd- or 3rd-degree traumatic brain injury with loss of consciousness > 30 min
- Epilepsy (personal or in first-degree relatives).
- Currently present psychiatric or neurological disease
- Regular use of medications that affect blood flow (e.g., ASA).
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
University Hospital for Psychiatry and Psychotherapy with Polyclinic
Tübingen, Baden-Wurttemberg, 72076
Andreas Fallgatter, Prof. Dr., 0049-7071-84858, Prof. Dr. Andreas Fallgatter <Andreas.Fallgatter@med.uni-tuebingen.de>
About this study
Official title: Investigation of the Influence of Transcranial Direct Current Stimulation (tDCS) on the Brain Activation Measured by fNIRS During the Decision Not to Smoke in High-risk Situations
Substance use disorders (SUD) are characterized by increased automatized responses to drug-related cues (cue-reactivity) and deficient cognitive control. Cue-reactivity (CR) can be elicited by internal (e.g. mood) or external (e.g. situations) cues closely related to consumption. Therefore, one aim for relapse prevention is to control CR by the enhancement of cognitive control, e.g., via noninvasive brain stimulation (NIBS) of cortical areas involved in inhibitory control. However, thus far, treatment effects of NIBS for relapse prevention in SUD are only moderate, despite clear neurophysiological targets. Critically, NIBS is commonly applied in highly standardized laboratory situation, not related to CR, neglecting the current individual (brain-) state. In the current study, relapse-relevant (brain-) states will be evoked in individual, naturalistic settings outside the laboratory and monitored by functional near-infrared spectroscopy (fNIRS; assessing cortical activation patterns) and heartrate variability (HRV; as a periphery physiological measure) to capture the optimal (cortical) state for subsequent NIBS by means of transcranial direct current stimulation (tDCS). The aim of this highly innovative approach is increasing the efficiency of relapse prevention in SUD. At its heart, multimodal measurements during real-world (substance-related) choices with high ecological validity will be used to identify markers for individual optimal target states for tDCS. In contrast to current approaches, the target brain state of the individual adaptively controls the tDCS to maximize therapeutic outcome. One obstacle is to clear the data from artefacts to interpret data at a single-trial level, which requires this proof-of-concept study. This data is prerequisite for further clinical randomized-controlled studies in patients with SUD.
Read the detailed description
Dependent smokers will be measured in the morning, adjusted to the usual time of getting up or a minimum 4-hour abstinence period. All participants will be measured on two days:
Day 1: First, after written consent to participate in the study, all inclusion and exclusion criteria are checked and standardized questionnaires are collected. To validate the activity in the dorsolateral prefrontal cortex (dlPFC) and in the orbitofrontal cortex (OFC) individually, two "localizer measurements" are performed. For the dlPFC, a go/nogo task will be used with smoke-associated and positive images; for the OFC, the same images from the dlPFC localizer will be used and viewed in a "passive viewing task" that will be pushed away by keypress.
Next, a modified version of a cue exposure follows for 5 min that has already been implemented in preliminary studies (Kroczek et al., 2016, 2017). All smokers have their own cigarettes, a lighter, and an ashtray on a table in front of them. The cue-exposure is done twice, once in a laboratory room and once in a naturalistic smoking setting. This condition is used as training for the Support Vector Machine (SVM).
This is followed by a cue exposure in which smokers are allowed to actually decide whether to smoke a cigarette or to resist. This condition occurs only outside, after the first part of the experiment has taken place. In this "50% condition", participants receive the instruction that they are allowed to take a drag on their cigarette after each prompt and they should take a drag in about half of the trials. Smoking behavior (puff on the cigarette/no puff on the cigarette) and also craving is noted by the experimenter.The goal of the first day is to train the SVM to detect maximum cue-reactivity concurrent to its cognitive control by response inhibition
Day 2: At most one week after time point 1, the SVM will be used to promote the cortical activity state that enables effective cue exposure therapy during the exposure condition in the smoking risk situation. With the aid of SVM, a tDCS intervention should be triggered at the optimal moment to further solidify extinction learning. This cue exposure measurement is used to classify successful inhibition of smoking. The measurement will take place in the naturalistic setting outside and the participants are NOT allowed to smoke but should increase their craving. As soon as the desired activity state is reached, indicated by the SVM, but at the latest after 5 minutes, tDCS is applied.
At the end of the experiment, the subjects will receive an information sheet on the consequences of smoking and information on the services offered by the Smoking Cessation Working Group at the University Hospital of Tübingen. In addition, the participants are psychoeducated that any exposure during the decision not to smoke helps to weaken the addiction memory. Information is provided that accordingly the follow-up survey on the cell phone will also record whether there were situations in which the smokers did not give in to craving in everyday life. This daily query is to take place in the evening over a period of 2 weeks by means of "Ecological Momentary Assessment" (EMA) on the smoker's own cell phone. EMA will be used to assess smoking behavior and potential situations on the current day in which the desire to smoke was triggered without giving in to this desire.
Total time expenditure for the participants will be approximately 3.5 hours, for which they will receive an expense allowance of 10€/hour.
All measurements will take place at the Department of Psychiatry and Psychotherapy of the University Hospital Tübingen in the Laboratory of Psycho-physiology and Optical Imaging (room U81, Osianderstr. 24, 72076 Tübingen) or on a bench close to the hospital.
Sample size:
The sample size is based on a preliminary study by the working group investigating cue exposure and tDCS interventions (Kroczek et al., 2017) with an effect size of d=0.66. Calculating the sample size in a within-subject design, with an alpha of 0.05 and a beta of 0.90 results in a required N of 28. Since the methodology differs from the previous experimental procedure by leaving the laboratory (with additional sources of interference by daylight and movement), additional participants shall be collected to a total sample of N=60.
Demographic data and questionnaires:
Participants' demographic data and information on current medication and handedness (Edinburgh Handedness Inventory (EHI)) will be collected in addition to smoking-related questionnaires including the FTND and Questionnaire on Smoking Urges (QSU-b). Smoking-related self-efficacy and abstinence motivation will also be assessed, in addition to the Positive and Negative Affect Schedule (PANAS), depressed mood (via the BDI-II), the State-Trait Anxiety Inventory, the level of general worry (via the WDQ), impulsivity (BIS-15,UPPS), general self-efficacy (via the SWE) and control beliefs (IE4).
A written follow-up survey about the tDCS will also be conducted to allow for a blinding check.
In addition, visual analog scales for the questions "how strong is your desire to smoke a cigarette" and "how strong is your stress experience" will be completed before and after each measurement.
Hypotheses:
The primary study goal is to quantify context effects. Here, we will examine the influence of context on different levels of cue reactivity.
The second primary study objective is to demonstrate the feasibility of SVM for identifying extinction processes and the feasibility that this SVM-based trigger can be used for tDCS. And lastly, we test the hypothesis that tDCS will have an impact on smoking behavior two weeks after the study.
Another secondary study objective concerns individual factors in the prediction of cue reactivity, immediate smoking in the 50:50 condition and number of smoked cigarettes within 14 days after tDCS.
- Conditions
- Tobacco Use Disorder
- Being tested
- active transcranial direct current stimulation (tDCS)
- Keywords
- cue-reactivity, smokers, fNIRS, naturalistic setting, dorsolateral prefrontal cortex (dlPFC), orbitofrontal cortex (OFC), transcranial direct current stimulation (tDCS), craving, heart-rate variability (HRV), galvanic skin response (GSR)
- Medical subject headings
- Tobacco Use Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
active transcranial direct current stimulation (tDCS)Device
Also called sham transcranial direct current stimulation (tDCS)
2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
| Study group | Role | What they receive |
|---|---|---|
| active transcranial direct current stimulation (tDCS) | Experimental | A single application of transcranial direct current stimulation (tDCS), anodal stimulation of the left dlPFC placed (10-20 position F3) and the reference electrode on the arm, intensity 2mA, with retangular electrodes, size 35cm2, current intensity is ramped up to 2mA over a period of 20 seconds, duration 15 minutes Receives: Device: active transcranial direct current stimulation (tDCS) |
| sham transcranial direct current stimulation (tDCS) | Sham comparator | A single application of transcranial direct sham stimulation (tDCS), with sponge electrodes, placed over left dlPFC (10-20 position F3) and the reference electrode on the arm, with retangular electrodes 35cm2,intensity is ramped up to 2mA over a period of 20 seconds duration and then switched off again at the end of 20 s ramp. To ensure that there are no differences in perception, this is applied in both verum and sham stimulation, duration 15 min Receives: Device: active transcranial direct current stimulation (tDCS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Craving ratings
verbally rated, scale from 0-100
Measured: Measurement day 1
Prefrontal fNIRS activity
Concentration changes of oxygenated (O2Hb) and deoxygenated (Hhb) hemoglobin in prefrontal regions of interest (dlPFC, OFC)
Measured: Measurement day 1
Activity of the sympathetic nervous system (SNS)
Galvanic skin response (GSR) regarding total peaks, amplitudes of peak (microsiemens) and frequency power of GSR as measures
Measured: Measurement day 1
Activity of the parasympathetic nervous system (PNS): Heart-rate variability (HRV)
Heart-rate Variabilty (HRV) indexes related to the PNS: RMSSD, pNN50 (in %), HF (in ms2).
Measured: Measurement day 1
Functional connectivity of dlPFC and OFC (fNIRS data)
cross-correlation between dlPFC and OFC time series
Measured: Measurement day 1
Multimodal SVM craving classifiers
The 5-dimensional training vectors (consisting of OFC activity, dlPFC activity, OFC-dlPFC connectivity, GSR, HRV) will be manually assigned a value between -1 and 1 based on the subjective craving ratings. The prediction of the SVM classifier will be tested in the 50:50 condition and related to smoking probability.
Measured: Measurement day 1
Efficacy of extinction learning
Assessment of the amount of self-reported smoked cigarettes and subjective craving (0-100) in a 2-week follow-up period (EMA)
Measured: 14 days after measurement day 2
Secondary outcomes (4)
Relationship between trait impulsivity scores and subjective craving
Pearson correlation
Measured: Measurement day 1
Relationship between trait impulsivity scores and number of smoked cigarettes
Pearson correlation (EMA questionnaires)
Measured: 14 days
Relationship between personality traits and state effects (self-efficacy, control beliefs) and craving
Pearson correlation of state and trait anxiety, WDQ, SER, IE-4 scores and subjective craving
Measured: Measurement day 1
Relationship between anxiety and general preoccupation and number of smoked cigarettes
Pearson correlation of state and trait anxiety, WDQ, number of smoked cigarettes (EMA questionnaires)
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2023
- Study start15 Oct 2022
- Primary completion10 Oct 2023 (estimated)
- Study completion15 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tobacco Use DisorderStudies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Collaborators
- NIRX Medizintechnik GmbH, Gustav-Meyer Allee 25, 13355 Berlin, Hetzler Stiftung für Suchtforschung und Prävention
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05875194
- Sponsor's protocol ID
- 495/2021B02
- Status last verified
- Aug 2022
- First submitted
- 26 Jan 2023
- Last updated
- 25 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Influence of Transcranial Direct Current Stimulation (tDCS) on the Brain Activation Measured by fNIRS During the Decision Not to Smoke in High-risk Situations
- ClinicalTrials.gov ID
- NCT05875194
- Acronym / sponsor ID
- 495/2021B02
- Conditions
- Tobacco Use Disorder
- Keywords
- cue-reactivity, smokers, fNIRS, naturalistic setting, dorsolateral prefrontal cortex (dlPFC), orbitofrontal cortex (OFC), transcranial direct current stimulation (tDCS), craving
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Collaborators
- NIRX Medizintechnik GmbH, Gustav-Meyer Allee 25, 13355 Berlin, Hetzler Stiftung für Suchtforschung und Prävention
- Study start
- 15 Oct 2022 (actual)
- Primary completion
- 10 Oct 2023 (estimated)
- Study completion
- 15 Dec 2023 (estimated)
- First posted
- 25 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Substance use disorders (SUD) are characterized by increased automatized responses to drug-related cues (cue-reactivity) and deficient cognitive control. Cue-reactivity (CR) can be elicited by internal (e.g. mood) or external (e.g. situations) cues closely related to consumption. Therefore, one aim for relapse prevention is to control CR by the enhancement of cognitive control, e.g., via noninvasive brain stimulation (NIBS) of cortical areas involved in inhibitory control. However, thus far, treatment effects of NIBS for relapse prevention in SUD are only moderate, despite clear neurophysiological targets. Critically, NIBS is commonly applied in highly standardized laboratory situation, not related to CR, neglecting the current individual (brain-) state. In the current study, relapse-relevant (brain-) states will be evoked in individual, naturalistic settings outside the laboratory and monitored by functional near-infrared spectroscopy (fNIRS; assessing cortical activation patterns) and heartrate variability (HRV; as a periphery physiological measure) to capture the optimal (cortical) state for subsequent NIBS by means of transcranial direct current stimulation (tDCS). The aim of this highly innovative approach is increasing the efficiency of relapse prevention in SUD. At its heart, multimodal measurements during real-world (substance-related) choices with high ecological validity will be used to identify markers for individual optimal target states for tDCS. In contrast to current approaches, the target brain state of the individual adaptively controls the tDCS to maximize therapeutic outcome. One obstacle is to clear the data from artefacts to interpret data at a single-trial level, which requires this proof-of-concept study. This data is prerequisite for further clinical randomized-controlled studies in patients with SUD.
Detailed description
Dependent smokers will be measured in the morning, adjusted to the usual time of getting up or a minimum 4-hour abstinence period. All participants will be measured on two days:
Day 1: First, after written consent to participate in the study, all inclusion and exclusion criteria are checked and standardized questionnaires are collected. To validate the activity in the dorsolateral prefrontal cortex (dlPFC) and in the orbitofrontal cortex (OFC) individually, two "localizer measurements" are performed. For the dlPFC, a go/nogo task will be used with smoke-associated and positive images; for the OFC, the same images from the dlPFC localizer will be used and viewed in a "passive viewing task" that will be pushed away by keypress.
Next, a modified version of a cue exposure follows for 5 min that has already been implemented in preliminary studies (Kroczek et al., 2016, 2017). All smokers have their own cigarettes, a lighter, and an ashtray on a table in front of them. The cue-exposure is done twice, once in a laboratory room and once in a naturalistic smoking setting. This condition is used as training for the Support Vector Machine (SVM).
This is followed by a cue exposure in which smokers are allowed to actually decide whether to smoke a cigarette or to resist. This condition occurs only outside, after the first part of the experiment has taken place. In this "50% condition", participants receive the instruction that they are allowed to take a drag on their cigarette after each prompt and they should take a drag in about half of the trials. Smoking behavior (puff on the cigarette/no puff on the cigarette) and also craving is noted by the experimenter.The goal of the first day is to train the SVM to detect maximum cue-reactivity concurrent to its cognitive control by response inhibition
Day 2: At most one week after time point 1, the SVM will be used to promote the cortical activity state that enables effective cue exposure therapy during the exposure condition in the smoking risk situation. With the aid of SVM, a tDCS intervention should be triggered at the optimal moment to further solidify extinction learning. This cue exposure measurement is used to classify successful inhibition of smoking. The measurement will take place in the naturalistic setting outside and the participants are NOT allowed to smoke but should increase their craving. As soon as the desired activity state is reached, indicated by the SVM, but at the latest after 5 minutes, tDCS is applied.
At the end of the experiment, the subjects will receive an information sheet on the consequences of smoking and information on the services offered by the Smoking Cessation Working Group at the University Hospital of Tübingen. In addition, the participants are psychoeducated that any exposure during the decision not to smoke helps to weaken the addiction memory. Information is provided that accordingly the follow-up survey on the cell phone will also record whether there were situations in which the smokers did not give in to craving in everyday life. This daily query is to take place in the evening over a period of 2 weeks by means of "Ecological Momentary Assessment" (EMA) on the smoker's own cell phone. EMA will be used to assess smoking behavior and potential situations on the current day in which the desire to smoke was triggered without giving in to this desire.
Total time expenditure for the participants will be approximately 3.5 hours, for which they will receive an expense allowance of 10€/hour.
All measurements will take place at the Department of Psychiatry and Psychotherapy of the University Hospital Tübingen in the Laboratory of Psycho-physiology and Optical Imaging (room U81, Osianderstr. 24, 72076 Tübingen) or on a bench close to the hospital.
Sample size:
The sample size is based on a preliminary study by the working group investigating cue exposure and tDCS interventions (Kroczek et al., 2017) with an effect size of d=0.66. Calculating the sample size in a within-subject design, with an alpha of 0.05 and a beta of 0.90 results in a required N of 28. Since the methodology differs from the previous experimental procedure by leaving the laboratory (with additional sources of interference by daylight and movement), additional participants shall be collected to a total sample of N=60.
Demographic data and questionnaires:
Participants' demographic data and information on current medication and handedness (Edinburgh Handedness Inventory (EHI)) will be collected in addition to smoking-related questionnaires including the FTND and Questionnaire on Smoking Urges (QSU-b). Smoking-related self-efficacy and abstinence motivation will also be assessed, in addition to the Positive and Negative Affect Schedule (PANAS), depressed mood (via the BDI-II), the State-Trait Anxiety Inventory, the level of general worry (via the WDQ), impulsivity (BIS-15,UPPS), general self-efficacy (via the SWE) and control beliefs (IE4).
A written follow-up survey about the tDCS will also be conducted to allow for a blinding check.
In addition, visual analog scales for the questions "how strong is your desire to smoke a cigarette" and "how strong is your stress experience" will be completed before and after each measurement.
Hypotheses:
The primary study goal is to quantify context effects. Here, we will examine the influence of context on different levels of cue reactivity.
The second primary study objective is to demonstrate the feasibility of SVM for identifying extinction processes and the feasibility that this SVM-based trigger can be used for tDCS. And lastly, we test the hypothesis that tDCS will have an impact on smoking behavior two weeks after the study.
Another secondary study objective concerns individual factors in the prediction of cue reactivity, immediate smoking in the 50:50 condition and number of smoked cigarettes within 14 days after tDCS.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| active transcranial direct current stimulation (tDCS) | Experimental | Device: active transcranial direct current stimulation (tDCS)A single application of transcranial direct current stimulation (tDCS), anodal stimulation of the left dlPFC placed (10-20 position F3) and the reference electrode on the arm, intensity 2mA, with retangular electrodes, size 35cm2, current intensity is ramped up to 2mA over a period of 20 seconds, duration 15 minutes |
| sham transcranial direct current stimulation (tDCS) | Sham comparator | Device: active transcranial direct current stimulation (tDCS)A single application of transcranial direct sham stimulation (tDCS), with sponge electrodes, placed over left dlPFC (10-20 position F3) and the reference electrode on the arm, with retangular electrodes 35cm2,intensity is ramped up to 2mA over a period of 20 seconds duration and then switched off again at the end of 20 s ramp. To ensure that there are no differences in perception, this is applied in both verum and sham stimulation, duration 15 min |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- informed consent
- daily cigarette consumption (already in the first half of the day)
Key exclusion criteria (8 listed)
- pre-existing diabetes mellitus (E10-E14) according to ICD-10
- Renal insufficiency from stage 3 of the Kidney Disease Outcomes Quality Initiative onwards
- Uncontrolled hypertension (I10.x according to ICD-10)
- Moderate or severe traumatic brain injury (GCS 3-12) or 2nd- or 3rd-degree traumatic brain injury with loss of consciousness > 30 min
- Epilepsy (personal or in first-degree relatives).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| active transcranial direct current stimulation (tDCS)Also: sham transcranial direct current stimulation (tDCS)2mA, over the left dlPFC (10-20 position F3), duration 15 minutes | Device | active transcranial direct current stimulation (tDCS), sham transcranial direct current stimulation (tDCS) |
Primary outcome
Craving ratings
Time frame: Measurement day 1
verbally rated, scale from 0-100
Prefrontal fNIRS activity
Time frame: Measurement day 1
Concentration changes of oxygenated (O2Hb) and deoxygenated (Hhb) hemoglobin in prefrontal regions of interest (dlPFC, OFC)
Activity of the sympathetic nervous system (SNS)
Time frame: Measurement day 1
Galvanic skin response (GSR) regarding total peaks, amplitudes of peak (microsiemens) and frequency power of GSR as measures
Activity of the parasympathetic nervous system (PNS): Heart-rate variability (HRV)
Time frame: Measurement day 1
Heart-rate Variabilty (HRV) indexes related to the PNS: RMSSD, pNN50 (in %), HF (in ms2).
Functional connectivity of dlPFC and OFC (fNIRS data)
Time frame: Measurement day 1
cross-correlation between dlPFC and OFC time series
Multimodal SVM craving classifiers
Time frame: Measurement day 1
The 5-dimensional training vectors (consisting of OFC activity, dlPFC activity, OFC-dlPFC connectivity, GSR, HRV) will be manually assigned a value between -1 and 1 based on the subjective craving ratings. The prediction of the SVM classifier will be tested in the 50:50 condition and related to smoking probability.
Efficacy of extinction learning
Time frame: 14 days after measurement day 2
Assessment of the amount of self-reported smoked cigarettes and subjective craving (0-100) in a 2-week follow-up period (EMA)
4 secondary outcomes
Relationship between trait impulsivity scores and subjective craving
Time frame: Measurement day 1
Relationship between trait impulsivity scores and number of smoked cigarettes
Time frame: 14 days
Relationship between personality traits and state effects (self-efficacy, control beliefs) and craving
Time frame: Measurement day 1
Relationship between anxiety and general preoccupation and number of smoked cigarettes
Time frame: 14 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2023.
- Individual participant dataSharing planned: No
Related trials for Tobacco Use Disorder
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
RecruitingObservational study
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
Oral Potentially Malignant Disorders, Oral Lichen Planus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing active transcranial direct current stimulation (tDCS) in people with Tobacco Use Disorder, run by University Hospital Tuebingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Agnes Kroczek, Dr. (0049-7071-2987103, mailto:Agnes.Kroczek@med.uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Craving ratings (time frame: Measurement day 1). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2023.